Bantam Pharmaceutical (United States)
Bantam Pharmaceutical is a private biotechnology company developing novel oral small molecule therapeutics for difficult-to-treat cancers, focusing on mitochondrial dynamics.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Bantam Pharmaceutical is a private biotechnology company based in Research Triangle Park, North Carolina, USA. It is developing novel, first-in-class oral small molecule therapeutics for difficult-to-treat hematological and solid tumors. The company's lead candidate is BTM-3566, an orally available small molecule initially focused on lymphomas such as DLBCL, MCL, and FL. Founded in 2015, the company pivoted to mitochondrial dynamics in 2017 and identified BTM-3566 in 2019.
History
Bantam Pharmaceutical was founded in 2015 based on acquired Harvard IP. In 2017, the company switched focus to mitochondrial dynamics. In 2019, BTM-3566 was identified as the first clinical candidate with an initial focus in lymphoma. In 2020, a CMC campaign and initiation of IND enabling studies occurred. From 2021-2022, the company moved to IND with Ph 1a/1b evidence of clinical efficacy. In 2025, the company initiated its first clinical trial for BTM-3566.
Products and positioning
BTM-3566
Orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphoma (DLBCL).
Recent events
Bantam Pharmaceutical names Michael Stocum CEO[4]
Reported:
Bantam Pharmaceutical announced that it had named Michael Stocum president and chief executive officer, succeeding founding CEO Mike Luther.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/bantam-pharmaceutical-united-states · Editorial policy · How profiles are compiled